@article{abdea7412b2d47eca8ce0f002e2a5c82,
title = "Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆",
keywords = "ESCAT, ESMO Clinical Practice Guideline (CPG), ESMO-MCBS, immunotherapy, non-oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), treatment, targeted therapy",
author = "{ESMO Guidelines Committee} and Hendriks, {L. E.} and Kerr, {K. M.} and J. Menis and Mok, {T. S.} and U. Nestle and A. Passaro and S. Peters and D. Planchard and Smit, {E. F.} and Solomon, {B. J.} and G. Veronesi and M. Reck",
note = "Funding Information: Manuscript editing support was provided by Fraser Simpson, Claire Bramley and Catherine Evans ( ESMO Guidelines staff); this support was funded by ESMO . Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urania Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino ( ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores, and Angela Corstorphine of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO . Matt Hellmann provided initial writing support during the conception of this guideline. ",
year = "2023",
month = apr,
day = "1",
doi = "10.1016/j.annonc.2022.12.013",
language = "English",
volume = "34",
pages = "358--376",
journal = "Annals of Oncology",
issn = "0923-7534",
number = "4",
}